To include your compound in the COVID-19 Resource Center, submit it here.

Senate budget deal whacks pharma, boosts NIH

The Senate is debating budget legislation that would cost drug companies tens of billions of dollars, increase NIH’s budget and help enhance market access for biosimilars.

Drug companies were surprised to learn Wednesday night that the Senate budget deal includes provisions that would shift billions of dollars in costs from Medicare Part D plans to pharmaceutical

Read the full 559 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers